Provided by Tiger Trade Technology Pte. Ltd.

IGC Pharma

0.3100
-0.0239-7.16%
Pre-market: 0.31600.0060+1.94%05:13 EDT
Volume:926.07K
Turnover:296.63K
Market Cap:32.05M
PE:-3.98
High:0.3350
Open:0.3280
Low:0.3061
Close:0.3339
52wk High:0.4700
52wk Low:0.2350
Shares:103.38M
Float Shares:90.33M
Volume Ratio:0.64
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0780
EPS(LYR):-0.0931
ROE:-83.34%
ROA:-50.31%
PB:3.96
PE(LYR):-3.33

Loading ...

IGC Pharma Q1 FY26 net loss widens 101% to $2.4 million; revenue falls 4% to $317,000

Reuters
·
May 16

IGC Pharma to present new Tau-PET biomarker research at Global Tau conference

TIPRANKS
·
May 15

IGC Pharma presents Tau-PET biomarker study at 2026 Global Tau Conference

Reuters
·
May 15

FOCUS-Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification

Reuters
·
Apr 30

Analysts Are Bullish on Top Healthcare Stocks: IGC Pharma (IGC), 60 Degrees Pharmaceuticals, Inc. (SXTP)

TIPRANKS
·
Apr 24

IGC Pharma adds Dallas site to Phase 2 CALMA trial for Alzheimer’s agitation drug IGC-AD1

Reuters
·
Apr 22

IGC Pharma Secures New Promissory Note Financing Agreements

TIPRANKS
·
Apr 21

IGC Pharma issues unregistered shares tied to $545,000 discounted notes in private placement

Reuters
·
Apr 21

IGC Pharma secures Colombian authorization for psilocybin research

TIPRANKS
·
Apr 20

IGC Pharma wins Colombia authorization for psilocybin research activities

Reuters
·
Apr 20

IGC Pharma says Phase 2 CALMA trial of IGC-AD1 reaches 80% enrollment

Reuters
·
Apr 14

Ascendiant Capital Markets raises IGC Pharma price target to $5.25

Reuters
·
Apr 09

IGC Pharma Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Apr 08

IGC Pharma adds Louisiana site to Phase 2 CALMA trial for Alzheimer’s agitation

Reuters
·
Apr 08

IGC announces activation of new clinical trial sate for Phase 2 CALMA trial

TIPRANKS
·
Apr 07

IGC Pharma enters national media partnership with New to The Street

TIPRANKS
·
Mar 30

IGC Pharma Q3 EPS $(0.01) Beats $(0.02) Estimate, Sales $213.000K Miss $325.000K Estimate

Benzinga Earnings
·
Mar 19

IGC Pharma reports 9-month revenue $969K

TIPRANKS
·
Mar 19

IGC Pharma 9M net loss attributable to common stockholders narrows 30% to USD 4.15 million

Reuters
·
Mar 19

IGC Pharma to Demonstrate AHA AI Platform at ADPD 2026

Reuters
·
Mar 18